- Home
- XENE vs RYTM Comparison
XENE vs RYTM Comparison
Compare XENE & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XENE | RYTM |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.8B |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XENE | RYTM |
|---|---|---|
| Price | $52.07 | $88.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $68.55 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.3M | 501.3K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,000.00 | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | $2,496.48 | $86.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.00 | $60.71 |
| 52 Week High | $62.91 | $122.20 |
Technical Indicators
Market Signals| Indicator | XENE | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 51.04 |
| Support Level | $39.93 | $82.43 |
| Resistance Level | $59.43 | $92.51 |
| Average True Range (ATR) | 1.71 | 3.76 |
| MACD | -0.16 | -0.19 |
| Stochastic Oscillator | 27.00 | 54.11 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.